Background: Patients taking methadone for opioid use disorder may desire transition to buprenorphine for a number of reasons. However, the current recommended approach for this transition generally takes weeks to months as an outpatient, causing considerable discomfort to the patient and a heightened risk of relapse during the transition period. Case: We describe the case of a patient on methadone maintenance who was rapidly transitioned to buprenorphine because of her desire to not return to her methadone clinic. In order to rapidly transition the patient from methadone to buprenorphine, naltrexone was administered to precipitate acute opioid withdrawal, which was followed soon after by buprenorphine induction. Discussion: Rapid transition from methadone maintenance to buprenorphine can be accomplished in inpatients by precipitating acute withdrawal with naltrexone, providing an effective alternative for patients who cannot tolerate the typical protracted methadone taper required prior to buprenorphine induction as an outpatient.
CasadontePP. Transfer from methadone to buprenorphine. 2013.
2.
HanonS, SeewaldRM, YangF, SchweitzerP, RosmanJ. Ventricular arrhythmias in patients treated with methadone for opioid dependence. J Interv Card Electrophysiol. 2010;28:19–22.
3.
Substance Abuse and Mental Health Services Administration (SAMHSA). Substance abuse treatment: Group therapy. Rockville, MD: Substance Abuse and Mental Health Services Administration;2005.
4.
BreenCL, HarrisSJ, LintzerisN. Cessation of methadone maintenance treatment using buprenorphine: transfer from methadone to buprenorphine and subsequent buprenorphine reductions. Drug Alcohol Depen. 2003;71:49–55.
5.
JohnsonS, MartinPR. Transitioning from methadone to buprenorphine maintenance in management of opioid use disorder during pregnancy. Am J Drug Alcohol Abuse. 2018;44:310–316.
6.
LawFD, BaileyJE, AllenDS, . The feasibility of abrupt methadone-buprenorphine transfer in British opiate addicts in an outpatient setting. Addict Biol. 1997;2:191–200.
7.
LevinFR, FischmanMW, ConnerneyI, FoltinRW. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. Am J Addict. 1997;6:105–116.
8.
MannelliP, PeindlKS, LeeT, BhatiaKS, LtW. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev. 2012;5:52–63.
9.
OrettiR. A retrospective evaluation of inpatient transfer from high-dose methadone to buprenorphine substitution therapy. J Subst Abuse Treat. 2015;57:102–105.
Substance Abuse and Mental Health Services Administration (SAMHSA). Medications for Opioid Use Disorder. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2018.
12.
RosadoJ, WalshSL, BigelowGE, StrainEC. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depen. 2007;90:261–269.
13.
Substance Abuse and Mental Health Services Administration (SAMHSA). Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.
14.
BammerG, BattissonL, WardJ, WilsonS. The impact on retention of expansion of an Australian public methadone program. Drug Alcohol Depen. 2000;58:173–180.
15.
CalsynDA, MalcyJA, SaxonAJ. Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. J Subst Abuse Treat. 2006;30:159–163.
16.
CushmanP.Jr., Ten years of methadone maintenance treatment: some clinical observations. Am J Drug Alcohol Abuse. 1977;4:543–553.
17.
DennisM, ScottCK. Managing addiction as a chronic condition. Addict Sci Clin Pract. 2007;4:45–55.
18.
GearingFR. Methadone maintenance treatment. Five years later-where are they now?Am J Public Health. 1974;64(Suppl 12):44–50.
19.
TermorshuizenF, KrolA, PrinsM, . Prediction of relapse to frequent heroin use and the role of methadone prescription: an analysis of the Amsterdam Cohort Study among drug users. Drug Alcohol Depen. 2005;79:231–240.
20.
GlasperA, ReedLJ, WetCJ, GossopM, BearnJ. Induction of patients with moderately severe methadone dependence onto buprenorphine. Addict Biol. 2005;10:149–155.
21.
UrbanV, SullivanR. Buprenorphine rescue from naltrexone-induced opioid withdrawal during relatively rapid detoxification from high-dose methadone: a novel approach. Psychiatry. 2008;5:56–58.
22.
CollinsED, KleberHD, WhittingtonRA, HeitlerNE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA. 2005;294(8):903–913.
23.
O'ConnorPG, KostenTR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998;279:229–234.
24.
EhretGB, DesmeulesJA, BroersB. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf. 2007;6:289–303.
25.
FanoeS, HvidtC, EgeP, JensenGB. Syncope and QT prolongation among patients treated with methadone for heroin dependence in the city of Copenhagen. Heart. 2007;93:1051–1055.
26.
FishmanMJ, WuLT, WoodyGE. Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence. Am J Psychiatry. 2011;168:675–679.
27.
GuptaA, LawrenceAT, KrishnanK, KavinskyCJ, TrohmanRG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891–899.
28.
JohnsonRE, StrainEC, AmassL. Buprenorphine: how to use it right. Drug Alcohol Depen. 2003;70:S59–S77.
29.
MartellBA, ArnstenJH, KrantzMJ, GourevitchMN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95:915–918.
30.
MittalL. Buprenorphine for the treatment of opioid dependence in pregnancy. J Perinat Neonatal Nurs. 2014;28:178–184.
31.
WedamEF, BigelowGE, JohnsonRE, NuzzoPA, HaigneyMC. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469–2475.
32.
WhitleySD, KuninsHV, ArnstenJH, GourevitchMN. Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. J Subst Abuse Treat. 2007;33:85–90.
33.
WinstockAR, LintzerisN, LeaT. Why do patients report transferring between methadone and buprenorphine?Drug Alcohol Rev. 2009;28:686–687.
34.
SuzukiJ, DeVidoJ, KalraI, . Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series. Am J Addict. 2015;24:10–14.
Hassanian-MoghaddamH, AfzaliS, PooyaA. Withdrawal syndrome caused by naltrexone in opioid abusers. Hum Exp Toxicol. 2014;33:561–567.
37.
NajiL, DennisBB, BaworM, . The association between age of onset of opioid use and comorbidity among opioid dependent patients receiving methadone maintenance therapy. Addict Sci Clin Pract. 2017;12:9.
38.
RonceroC, BarralC, Rodriguez-CintasL, . Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: the PROTEUS study. Psychiatry Res. 2016;243:174–181.
39.
ManhapraA, QuinonesL, RosenheckR. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82–89.
